Beyond the Genetic Ceiling: How Scholar Rock's FDA Approval for Isembyld Unlocks the Muscle-Directed Neuromuscular Economy
Dr. Dereck Mush, MD, MBADavid L. Hallal
Chairman and CEO, Scholar Rock
- Industry
- Neuromuscular biopharma and rare diseases
- Based in
- Cambridge, USA
- Company funding
- Undisclosed
- Region
- North America
Biopharmaceutical executive with experience building and commercializing rare-disease businesses.
Leads Scholar Rock and its selective growth-factor programs.
David L. Hallal is Chairman and CEO of Scholar Rock.
More founders in Neuromuscular biopharma and rare diseases
- Mo Qatanani, Ph.D.
Scholar Rock
Related on The Signal
Dr. Dereck Mush, MD, MBA
Top 25 Cardiologists to Follow on LinkedIn in 2026
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Digital Health Funding Hit $7.4B in H1 2026. Here Is Where the Money Actually Went.
Digital Health Funding Hit $7.4B in H1 2026. Here Is Where the Money Actually Went.
Dr. Dereck Mush, MD, MBA
Inverting the GLP-1 Axis: Antagonism and the Unintended Metabolic Casualties of Bariatric Surgery
Dr. Dereck Mush, MD, MBAKeep exploring